AMYNDAS PHARMACEUTICALS SINGLEMEMBER PC
Desconocido
FIBROTARGET: Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases
AMYNTAS FARMAKEUTIKA PROIONTA MONOPROSOPI IDIOTIKI KEFALAIOUCHIKI ETAIREIA
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2022-DISEASE-06-two-stage
Fibrostenosis is the driving reason for the persistent need in bowel resections in inflammatory bowel diseases (IBD). Current IBD therapies...
2023-04-24 - 2028-03-31 | Financiado
2023-04-24 - 2028-03-31 | Financiado
DIREKT: Disarming the intravascular innate immune response to improve treatment modalities for chronic kidne...
AMYNTAS FARMAKEUTIKA PROIONTA MONOPROSOPI IDIOTIKI KEFALAIOUCHIKI ETAIREIA
participó en un
FP7:
Chronic kidney disease is world wide a major cause of end-stage renal disease (ESRD). 800.000 patients in Europe and in the US, respectively...
Financiado
Financiado
* No se disponen de datos de la empresa actual.